RajenJModyMDMS

Pediatric Hematology & Oncology • Ann Arbor, MI

Pediatric Solid Tumor Oncology

Ruth Heyn Professor of Pediatric Oncology, Director, Division of Pediatric Hematology/Oncology/ BMT, Director, Pediatric Developmental Therapeutics and Phase-I Program, Michigan Medicine

Join to view full profile

Dr. Mody is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mody's full profile

Already have an account?

Office
1500 E Medical Center Dr
Ann Arbor, MI 48109
Phone+1 734-936-4000

Education & Training

Scool Of Public Health, University Of MichiganM.S., Clinical Trial Design and Biostatistics, 2001 - 2003
University of MichiganFellowship, Pediatric Hematology/Oncology, 1997 - 2000
SUNY Downstate Health Sciences UniversityResidency, Pediatrics, 1994 - 1997
N.H.L Municipal Medical CollegeClass of 1989

Certifications & Licensure

MI State Medical License 1997 - 2025
OH State Medical License 2006 - 2022
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
Active, not recruiting
Phase 3
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma Start of enrollment: 2008 Apr 01
Completed
Phase 1
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies Start of enrollment: 2008 Jul 17
Recruiting
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Start of enrollment: 2009 Jul 13
Active, not recruiting
Phase 3
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin Start of enrollment: 2010 Oct 04
Active, not recruiting
Phase 1
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Start of enrollment: 2011 Apr 04
Completed
Phase 3
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 1
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Start of enrollment: 2012 Nov 14
Completed
Phase 1
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma Start of enrollment: 2013 Nov 01
Completed
Phase 1
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12
Completed
Phase 2
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2013 Jan 31
Completed
Phase 1, Phase 2
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2014 Mar 28
Completed
Phase 1, Phase 2
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Start of enrollment: 2014 May 16
Completed
Phase 1, Phase 2
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Start of enrollment: 2014 Sep 01
Completed
Phase 1
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Start of enrollment: 2015 Dec 11
Completed
Phase 1
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Start of enrollment: 2018 Aug 13
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group P...
Margaret E Macy, Rajen Mody, Joel M Reid, Jin Piao, Lauren Saguilig
JCO Precision Oncology. 2024-09-01
Long-Term Tumor Stability After First-Line Treatment With Larotrectinib in an Infant With NTRK2 Fusion-Positive High-Grade Glioma.
Jillian Simoneau, Patricia Robertson, Karin Muraszko, Cormac O Maher, Hugh Garton
Journal of the National Comprehensive Cancer Network. 2024-09-01
Concurrent primary mediastinal germ cell tumor and acute myeloid leukemia: Case report of sustained remission and review of the literature.
Kristina Zalewski, Evan Cantor, Roland Chu, Rajen Mody, Greg Yanik
Pediatric Blood & Cancer. 2024-07-01

Lectures

Where Are We Now?
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Phase II trial of irinotecan/temozolomide/dinutuximab/granulocyte macrophage colony stimulating factor (I/T/DIN/GMCSF) in children with relapsed/refractory neuroblasto...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Authored Content

Pediatric Melanoma and Aggressive Spitz Tumors: A Retrospective Diagnostic, Exposure and Outcome AnalysisJanuary 2018

Press Mentions

A Novel ATXN1-DUX4 Fusion Expands the Spectrum of ‘CIC-Rearranged Sarcoma’ of the CNS to Include Non-CIC AlterationsFebruary 7th, 2021
Probing Why Cancer Outcomes Are Worse for Minority KidsJune 11th, 2018
Pediatric Melanoma and Aggressive Spitz Tumors: A Retrospective Diagnostic, Exposure and Outcome AnalysisJanuary 3rd, 2018
Join now to see all